ER Stress

The endoplasmic reticulum folds proteins and makes lipids, and it signals when it cannot keep up. In most Alzheimer's accounts ER stress appears late, as a consequence — the unfolded protein response firing because misfolded protein has accumulated. In this corpus it appears early, and for a different reason: not because the ER is failing to fold, but because the place where it touches the mitochondrion is doing too much.

The contact site, not the organelle

The load-bearing structure here is the mitochondria-associated ER membrane (MAM) — the apposition where ER and mitochondrion meet and exchange lipids and calcium. Area-Gómez (submission 133) argues that Alzheimer's disease is fundamentally a lipid disorder localised to that contact, and the anatomical detail that makes the argument bite is that γ-secretase activity is localised in the MAM. The final step of the amyloidogenic pathway can therefore only take place there.

MAM functions, as the submission enumerates them: phospholipid synthesis, cholesterol and steroid metabolism, sphingolipid metabolism including sphingomyelin and ceramide, glucose homeostasis, calcium trafficking, and mitochondrial oxidative metabolism. A structure carrying that many jobs is a structure whose dysregulation looks like many different diseases at once.

C99 as a signal, not a waste product

The distinctive claim is about the APP fragment C99. It is read not as a toxic intermediate but as a cholesterol sensor — a signal the cell raises when it needs cholesterol moved. The lesion is that the signal is never switched off. C99 accumulates at the MAM, contact function is upregulated rather than lost, and the consequences follow from a correction mechanism running continuously rather than from a poison.

This reframes the direction of causality. Elsewhere in the corpus, C99's Tyr682-phosphorylated form is what inhibits the v-ATPase and blocks lysosomal acidification. Two frameworks, one fragment, arrived at independently — which is the kind of convergence the corpus weighs heavily.

What would refute it

The corpus's evaluation of this programme is unusually specific about its falsifiers, and they are worth keeping on the concept page because they are testable now:

• a direct measurement of contact function in Alzheimer neurons — human tissue or well-validated models — finding it normal or reduced would remove the theory's foundation, since the central quantitative claim is directional
• serum lipid signatures that fail to precede phosphorylated tau in a longitudinal design would break the "upstream" claim, which currently rests on cross-sectional Colombian data
• a demonstration that C99 accumulation requires prior tau pathology, inflammation or lysosomal failure would make the sensor a passenger
• normalising contact function and leaving the disease unchanged, now possible with a tool compound

Adjacent lines

The MAM is also where the corpus's ceramide work lands — the ER–mitochondria weld read as the single structure in which the lipid disorder and the energy disorder are the same buckling. And van der Kant's finding that cholesterol esterification (an ACAT1 reaction, ACAT1 being a contact-site enzyme) mediates the statin effect on tau puts a third independent line through the same address.

Related

Membrane Biophysics · Cholesterol Transport · Lipid Transport · Lipid Dysregulation · Lysosomal Dysfunction · Energy Metabolism · Endosomal Nexus